Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Long-Term Deferred Tax (2024 - 2025)

Puma Biotechnology (PBYI) has disclosed Long-Term Deferred Tax for 5 consecutive years, with $7.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax changed N/A year-over-year to $7.1 million, compared with a TTM value of $7.1 million through Sep 2025, changed N/A, and an annual FY2024 reading of $7.1 million, changed N/A over the prior year.
  • Long-Term Deferred Tax was $7.1 million for Q3 2025 at Puma Biotechnology, roughly flat from $7.1 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $383.5 million in Q4 2021 and bottomed at $2.9 million in Q4 2022.
  • Average Long-Term Deferred Tax over 4 years is $69.1 million, with a median of $7.1 million recorded in 2024.
  • Peak annual rise in Long-Term Deferred Tax hit 99.23% in 2022, while the deepest fall reached 99.23% in 2022.
  • Year by year, Long-Term Deferred Tax stood at $383.5 million in 2021, then crashed by 99.23% to $2.9 million in 2022, then surged by 140.65% to $7.1 million in 2024, then changed by 0.0% to $7.1 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for PBYI at $7.1 million in Q3 2025, $7.1 million in Q2 2025, and $7.1 million in Q1 2025.